Fontolizumab: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
CSV import |
||
| Line 10: | Line 10: | ||
{{antineoplastic-drug-stub}} | {{antineoplastic-drug-stub}} | ||
{{short-articles-ni}} | {{short-articles-ni}} | ||
{{No image}} | |||
Latest revision as of 17:46, 10 February 2025
Fontolizumab, with trade name (HuZAF), is a humanized monoclonal antibody that targets IFN-γ used in the treatment of Crohn's disease.
| Immunosuppressive drugs / Immunosuppressants (L04) | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Cytokine receptor modulators | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!
